CARGO Therapeutics, Inc. (CRGX)
Aug 19, 2025 - CRGX was delisted (reason: acquired by Concentra Biosciences)
4.470
-0.070 (-1.54%)
Inactive · Last trade price on Aug 18, 2025
CARGO Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CARGO Therapeutics stock had an average target of 5.33, with a low estimate of 4.00 and a high estimate of 7.00.
Price Target: $5.33 (+19.24%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 8, 2025.
Analyst Ratings
The average analyst rating for CARGO Therapeutics stock from 7 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold Maintains $3.7 → $5 | Hold | Maintains | $3.7 → $5 | +11.86% | Jul 8, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $32 → $7 | Strong Buy → Hold | Downgrades | $32 → $7 | +56.60% | Jan 30, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $34 → $4 | Buy → Hold | Downgrades | $34 → $4 | -10.51% | Jan 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2025 |
| JP Morgan | JP Morgan | Buy → Sell Downgrades n/a | Buy → Sell | Downgrades | n/a | n/a | Jan 30, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.86
from -3.72
EPS Next Year
-2.41
from -2.86
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.56 | -0.66 | |||
| Avg | -2.86 | -2.41 | |||
| Low | -4.31 | -4.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.